Expression and clinical significance of stem cell marker CD133 in human neuroblastoma.
World J Pediatr
; 4(1): 58-62, 2008 Feb.
Article
em En
| MEDLINE
| ID: mdl-18402255
ABSTRACT
BACKGROUND:
Recent evidences indicate that CD133, a kind of transmembrane protein, can be used as a marker to isolate stem cells from tumors originating from neural crest. This study was undertaken to explore the expression and clinical significance of stem cell marker CD133 in neuroblastoma (NB).METHODS:
Immunohistochemical staining was used to detect the expression of CD133 in 32 patients with NB and 8 patients with ganglioneuroblastoma (GNB). The relationships were analyzed among CD133 expression, international neuroblastoma staging system (INSS) stages, pathological classification, and postoperative survival time of NB patients.RESULTS:
The expression rates of CD133 in NB and GNB were 46.9% (15/32) and 37.5% (3/8) respectively, mainly in cytoplasm of neuroblastoma cells. The expression rates of stage 1-2, stage 3-4 and stage 4S were 30.7%, 57.9% and 37.5%, respectively. The differences in various stages were significant (P<0.05). The positive rate of CD133 in patients with unfavorable histology (52.4%) was significantly higher than that in patients with favorable histology (36.8%) (P=0.007). The survival time of CD133 negative patients was significantly longer than that of CD133 positive patients (P=0.026).CONCLUSIONS:
CD133 which might be correlated with the development and progression of NB can serve as one of the important indicators for prognosis of NB.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Células-Tronco Neoplásicas
/
Glicoproteínas
/
Biomarcadores Tumorais
/
Antígenos CD
/
Neuroblastoma
Tipo de estudo:
Prognostic_studies
Limite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article